Bio-IT World | Research continues to uncover the underlying biology of SARS-CoV-2 and reveal some surprises. A German team found that 35% of their healthy controls had pre-existing SARS-CoV-2 cross-reactive T cells, and several groups are narrowing down the gene expression signatures that might explain why COVID-19 is so severe in some patients.

Bio-IT World July featured exciting new, products, and partnerships from around the bio-IT community from innovating companies, organizations, and universities, including Celsius Therapeutics, Twist Bioscience, and more.

Bio-IT World | A new collaborative study suggests that infection and exposure to coronaviruses induces long-lasting memory T cells, which could help in the management of the current pandemic and in vaccine development against COVID-19. This, plus more, is included in this week’s COVID-19 news from the biotech and research industries.

Bio-IT World Contributed Commentary | The last three years we have witnessed an exponential expansion of the cell and gene therapy space, both in the number of cell and gene therapies approved or in development, and the real and projected values of the market. This growth is rapidly changing the way we think about what medicines are.

Bio-IT World | It seems like a very long time ago, now, that Illumina and Pacific Biosciences dissolved their merger agreement, but in fact their announcement is just about six months old. Since then, PacBio has been busy reestablishing itself as an independent business and looking ahead, their sights set on the human genome sequencing market.

Bio-IT World Contributed Commentary | Mass spectrometry has transitioned from being used mostly in routine analytical applications to becoming a powerful biological method for protein quantitation.